2021
Delay Discounting and Adjuvant Endocrine Therapy Adherence in Hormone Receptor-Positive Breast Cancer
Vaughn JE, Ammermann C, Lustberg MB, Bickel WK, Stein JS. Delay Discounting and Adjuvant Endocrine Therapy Adherence in Hormone Receptor-Positive Breast Cancer. Health Psychology 2021, 40: 398-407. PMID: 34323542, DOI: 10.1037/hea0001077.Peer-Reviewed Original ResearchConceptsEndocrine therapy adherenceTherapy adherenceHormone receptor-positive breast cancerAdjuvant endocrine therapy adherenceReceptor-positive breast cancerOral endocrine therapyBreast cancer survivorsBreast cancer patientsSelf-reported adherencePatient-centered factorsBrief behavioral interventionCross-sectional associationsPotential therapeutic targetMaladaptive health behaviorsEndocrine therapyMedication nonadherenceCancer survivorsCancer patientsRisk factorsBreast cancerTherapeutic targetHealth behaviorsPatientsBehavioral interventionsSurvivors
2014
CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth
Mathsyaraja H, Thies K, Taffany D, Deighan C, Liu T, Yu L, Fernandez S, Shapiro C, Otero J, Timmers C, Lustberg M, Chalmers J, Leone G, Ostrowski M. CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth. Oncogene 2014, 34: 3651-3661. PMID: 25241894, PMCID: PMC4369473, DOI: 10.1038/onc.2014.294.Peer-Reviewed Original ResearchConceptsTumor-infiltrating myeloid cellsMetastatic tumor growthMyeloid cellsMiR-21Breast cancerTumor growthHuman metastatic breast cancerMetastatic tumor burdenMetastatic breast cancerPro-tumor functionsAnti-angiogenic genesAttractive therapeutic targetTumor cell proliferationPro-angiogenic propertiesMature myeloid cellsTumor burdenMonocytes correlatesPoor prognosisMelanoma metastasesMouse modelTherapeutic targetSolid tumorsOncogenic roleSurvival rateTherapeutic efficacy